190 related articles for article (PubMed ID: 12010787)
1. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.
DeSimone J; Koshy M; Dorn L; Lavelle D; Bressler L; Molokie R; Talischy N
Blood; 2002 Jun; 99(11):3905-8. PubMed ID: 12010787
[TBL] [Abstract][Full Text] [Related]
2. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
Koshy M; Dorn L; Bressler L; Molokie R; Lavelle D; Talischy N; Hoffman R; van Overveld W; DeSimone J
Blood; 2000 Oct; 96(7):2379-84. PubMed ID: 11001887
[TBL] [Abstract][Full Text] [Related]
3. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.
Saunthararajah Y; Hillery CA; Lavelle D; Molokie R; Dorn L; Bressler L; Gavazova S; Chen YH; Hoffman R; DeSimone J
Blood; 2003 Dec; 102(12):3865-70. PubMed ID: 12907443
[TBL] [Abstract][Full Text] [Related]
4. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
Molokie R; Lavelle D; Gowhari M; Pacini M; Krauz L; Hassan J; Ibanez V; Ruiz MA; Ng KP; Woost P; Radivoyevitch T; Pacelli D; Fada S; Rump M; Hsieh M; Tisdale JF; Jacobberger J; Phelps M; Engel JD; Saraf S; Hsu LL; Gordeuk V; DeSimone J; Saunthararajah Y
PLoS Med; 2017 Sep; 14(9):e1002382. PubMed ID: 28880867
[TBL] [Abstract][Full Text] [Related]
5. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.
Saunthararajah Y; DeSimone J
Semin Hematol; 2004 Oct; 41(4 Suppl 6):11-6. PubMed ID: 15534852
[TBL] [Abstract][Full Text] [Related]
6. DNA hypo-methylating agents and sickle cell disease.
Saunthararajah Y; Lavelle D; DeSimone J
Br J Haematol; 2004 Sep; 126(5):629-36. PubMed ID: 15327513
[TBL] [Abstract][Full Text] [Related]
7. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Borba R; Lima CS; Grotto HZ
J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
[TBL] [Abstract][Full Text] [Related]
8. The role of fetal hemoglobin-enhancing agents in thalassemia.
Lal A; Vichinsky E
Semin Hematol; 2004 Oct; 41(4 Suppl 6):17-22. PubMed ID: 15534853
[TBL] [Abstract][Full Text] [Related]
9. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease.
Atweh GF; Schechter AN
Curr Opin Hematol; 2001 Mar; 8(2):123-30. PubMed ID: 11224687
[TBL] [Abstract][Full Text] [Related]
11. 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens.
Dover GJ; Charache S; Boyer SH; Vogelsang G; Moyer M
Blood; 1985 Sep; 66(3):527-32. PubMed ID: 2411310
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
13. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
Ballas SK; Connes P;
Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
[TBL] [Abstract][Full Text] [Related]
14. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.
Maier-Redelsperger M; de Montalembert M; Flahault A; Neonato MG; Ducrocq R; Masson MP; Girot R; Elion J
Blood; 1998 Jun; 91(12):4472-9. PubMed ID: 9616141
[TBL] [Abstract][Full Text] [Related]
15. Induction of fetal hemoglobin in the treatment of sickle cell disease.
Fathallah H; Atweh GF
Hematology Am Soc Hematol Educ Program; 2006; ():58-62. PubMed ID: 17124041
[TBL] [Abstract][Full Text] [Related]
16. Therapies to increase fetal hemoglobin in sickle cell disease.
Steinberg MH
Curr Hematol Rep; 2003 Mar; 2(2):95-101. PubMed ID: 12901139
[TBL] [Abstract][Full Text] [Related]
17. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
Steinberg MH; Lu ZH; Barton FB; Terrin ML; Charache S; Dover GJ
Blood; 1997 Feb; 89(3):1078-88. PubMed ID: 9028341
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production.
Dover GJ; Humphries RK; Moore JG; Ley TJ; Young NS; Charache S; Nienhuis AW
Blood; 1986 Mar; 67(3):735-8. PubMed ID: 2418898
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]